CD33 exon 2 single nucleotide polymorphism (SNP) rs12459419 influences the alternative splicing of CD33. The presence of rs12459419 in exon 2 affects the exonic enhancer binding site for SRSF2, thereby resulting in the loss of exon 2 (shown in red) in the T allele. The loss of exon 2 results in a shorter CD33 isoform lacking the IgV domain, which is recognized by gemtuzumab ozogamicin (GO) and currently used antibodies. Reprinted with permission. © 2017 American Society of Clinical Oncology. All rights reserved. Lamba, JK et al: J Clin Oncol Vol. 35, 2017: 2674-2682.

CD33 exon 2 single nucleotide polymorphism (SNP) rs12459419 influences the alternative splicing of CD33. The presence of rs12459419 in exon 2 affects the exonic enhancer binding site for SRSF2, thereby resulting in the loss of exon 2 (shown in red) in the T allele. The loss of exon 2 results in a shorter CD33 isoform lacking the IgV domain, which is recognized by gemtuzumab ozogamicin (GO) and currently used antibodies. Reprinted with permission. © 2017 American Society of Clinical Oncology. All rights reserved. Lamba, JK et al: J Clin Oncol Vol. 35, 2017: 2674-2682.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal